A Phase 1 interventional study of LY4100511 (DC-853) and [14C]-LY4100511 (DC-853) Administered oral dose in Healthy, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-24.
Sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study has two parts, Part A and Part B. The purpose of Part A is to determine the absorption, metabolism, and excretion (AME) of [14C]-LY4100511 and to characterize and determine the metabolites present in plasma, urine, and feces in healthy male participants after a single oral dose of LY4100511. The purpose of Part B is to determine the absolute bioavailability of LY4100511 in humans, to further analyze the rate and routes of excretion, including the mass balance, and to further investigate the pharmacokinetics (PK) of [14C]-LY4100511, LY4100511, and TRA.
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 4 (40%) have results posted.
First submitted after DICE Therapeutics, Inc. became part of Eli Lilly and Company.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Have a 12-lead abnormality that, in the opinion of the Investigator
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single oral dose 1 or dose 2 unlabeled LY4100511 (tablet formulation) administered with a dose 1 \[14C\]-LY4100511 capsule containing approximately 100 µCi (3.7 MBq) of radioactivity in the fasted state
Drug: LY4100511 (DC-853) · Drug: [14C]-LY4100511 (DC-853) Administered oral dose
Participants will receive a single oral dose 1 or dose 2 unlabeled LY4100511 (tablet formulation) in the fasted state, followed by a single intravenous (IV) dose of of \[14C\]-LY4100511, containing ≤1 μCi (≤37 kBq) of radioactivity, administered as an infusion.
Drug: LY4100511 (DC-853) · Drug: [14C]-LY4100511 (DC-853)
Administered oral dose
Administered oral dose
Administered oral dose
Administered IV infusion
Part A: Total Radioactivity Recovery and Excretion (TRA)
Total radioactivity recovery and excretion (fet1-t2 and Aet1-t2) in urine and feces (and vomitus, if available)
Time frame: Up until Day 15
Part A: Pharmacokinetic (PK): Area Under the Concentration from Time 0 to Infinity (AUC0-∞) for [14C] LY4100511
Time frame: Up until Day 15
Part A: Pharmacokinetic (PK): Area Under the Concentration from Time 0 to Infinity (AUC0-∞) for LY4100511
Time frame: Up until Day 15
Part A: Pharmacokinetic (PK): Area Under the Concentration from Time 0 to Infinity (AUC0-∞) for TRA
Time frame: Up until Day 15
Part A: PK Area Under Concentration from 0 to Last Measurable Concentration (AUC0-tlast) for [14C] LY4100511
Time frame: Up until Day 15
Part A: PK Area Under Concentration from 0 to Last Measurable Concentration (AUC0-tlast) for LY4100511
Time frame: Up until Day 15
Part A: PK Area Under Concentration from 0 to Last Measurable Concentration (AUC0-tlast) for TRA
Time frame: Up until Day 15
Part A: PK Maximum Observed Plasma Concentration (Cmax) for [14C] LY4100511
Time frame: Up until Day 15
Part A: PK Maximum Observed Plasma Concentration (Cmax) for LY4100511
Time frame: Up until Day 15
Part A: PK Maximum Observed Plasma Concentration (Cmax) for TRA
Time frame: Up until Day 15
Part A: PK Time to Maximum Observed Plasma Concentration (tmax) for [14C] LY4100511
Time frame: Up until Day 15
Part A: PK Time to Maximum Observed Plasma Concentration (tmax) for LY4100511
Time frame: Up until Day 15
Part A: PK Time to Maximum Observed Plasma Concentration (tmax) for TRA
Time frame: Up until Day 15
Part A: PK Terminal Elimination Half Life (t1/2) for [14C] LY4100511
Time frame: Up until Day 15
Part A: PK Terminal Elimination Half Life (t1/2) for LY4100511
Time frame: Up until Day 15
Part A: PK Terminal Elimination Half Life (t1/2) for TRA
Time frame: Up until Day 15
Part A: Urinary Recovery and Excretion of TRA (Aet1-t2)
Time frame: Up until Day 15
Part A: Urinary Recovery and Excretion of [14C] LY4100511 (Aet1-t2)
Time frame: Up until Day 15
Part A: Renal clearance of [14C] LY4100511 (CLR)
Time frame: Up until Day 15
Part B: Pharmacokinetic (PK): absolute bioavailability (Fabs) of LY4100511
Time frame: Up until Day 6
Part B: Recovery of TRA in urine and feces
Time frame: Up until Day 6
Part B: Recovery of [14C]-LY4100511 in feces (Aet1-t2) following IV dosing
Time frame: Up until Day 6
Part B: Recovery of [14C]-LY4100511 in urine (Aet1-t2) following IV dosing
Time frame: Up until Day 6
Part B: PK Area Under Concentration from 0 to Last Measurable Concentration (AUC0-tlast) of LY4100511 following IV dosing
Time frame: Up until Day 6
Part B: PK Maximum Observed Plasma Concentration (Cmax) of LY4100511following IV dosing
Time frame: Up until Day 6
Part B: PK Time to Maximum Observed Plasma Concentration (tmax) of LY4100511following IV dosing
Time frame: Up until Day 6
Part B: PK Terminal Elimination Half Life (t1/2) following IV dosing
Time frame: Up until Day 6
Part B: PK Clearance (CL) following IV dosing
Time frame: Up until Day 6
Part B: PK renal clearance (CLr) following IV dosing [Time Frame: Up until Day 6]
Time frame: Up until Day 6
Number of Participants with One or More Adverse Events (AEs), and Serious Adverse Events (SAEs) considered by the investigator to be related to study drug administration
A summary of AEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events Module.
Time frame: Up until Day 8
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2024 to primary completion in Dec 2024, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Simepdekinra
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company →